Immunovia Ab Stock Performance
| IMMVF Stock | USD 0.05 0.00 0.00% |
The company retains a Market Volatility (i.e., Beta) of 0.0, which attests to not very significant fluctuations relative to the market. the returns on MARKET and Immunovia are completely uncorrelated.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Immunovia AB has generated negative risk-adjusted returns adding no value to investors with long positions. Despite nearly stable basic indicators, Immunovia is not utilizing all of its potentials. The current stock price disturbance, may contribute to mid-run losses for the stockholders. ...more
| Begin Period Cash Flow | 468.5 M | |
| Total Cashflows From Investing Activities | -23.8 M | |
| Free Cash Flow | -176.8 M |
Immunovia |
Immunovia Relative Risk vs. Return Landscape
If you would invest 5.21 in Immunovia AB on September 30, 2025 and sell it today you would earn a total of 0.00 from holding Immunovia AB or generate 0.0% return on investment over 90 days. Immunovia AB is currently producing negative expected returns and takes up 0.0% volatility of returns over 90 trading days. Put another way, 0% of traded pink sheets are less volatile than Immunovia, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Immunovia Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Immunovia's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Immunovia AB, and traders can use it to determine the average amount a Immunovia's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| IMMVF |
Based on monthly moving average Immunovia is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Immunovia by adding Immunovia to a well-diversified portfolio.
Immunovia Fundamentals Growth
Immunovia Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Immunovia, and Immunovia fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Immunovia Pink Sheet performance.
| Return On Equity | -0.38 | |||
| Return On Asset | -0.26 | |||
| Current Valuation | 51.96 M | |||
| Shares Outstanding | 22.63 M | |||
| Price To Earning | (13.76) X | |||
| Price To Book | 2.37 X | |||
| Price To Sales | 829.03 X | |||
| Revenue | 844 K | |||
| EBITDA | (135.47 M) | |||
| Cash And Equivalents | 11.65 M | |||
| Cash Per Share | 0.09 X | |||
| Total Debt | 5.11 M | |||
| Debt To Equity | 0.10 % | |||
| Book Value Per Share | 0.04 X | |||
| Cash Flow From Operations | (152.65 M) | |||
| Total Asset | 493.81 M | |||
| Current Asset | 6.72 M | |||
| Current Liabilities | 897 K | |||
About Immunovia Performance
By analyzing Immunovia's fundamental ratios, stakeholders can gain valuable insights into Immunovia's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Immunovia has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Immunovia has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Immunovia AB , a diagnostic company, develops and commercializes blood tests in Sweden and internationally. Immunovia AB was incorporated in 2007 and is headquartered in Lund, Sweden. Immunovia operates under Diagnostics Research classification in the United States and is traded on OTC Exchange. It employs 69 people.Things to note about Immunovia AB performance evaluation
Checking the ongoing alerts about Immunovia for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Immunovia AB help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Immunovia AB generated a negative expected return over the last 90 days | |
| Immunovia AB has some characteristics of a very speculative penny stock | |
| The company reported the revenue of 844 K. Net Loss for the year was (155.97 M) with profit before overhead, payroll, taxes, and interest of 15.81 M. | |
| Immunovia AB has accumulated about 11.65 M in cash with (152.65 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.09, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 36.0% of the company shares are held by company insiders |
- Analyzing Immunovia's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Immunovia's stock is overvalued or undervalued compared to its peers.
- Examining Immunovia's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Immunovia's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Immunovia's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Immunovia's pink sheet. These opinions can provide insight into Immunovia's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Immunovia Pink Sheet analysis
When running Immunovia's price analysis, check to measure Immunovia's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunovia is operating at the current time. Most of Immunovia's value examination focuses on studying past and present price action to predict the probability of Immunovia's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunovia's price. Additionally, you may evaluate how the addition of Immunovia to your portfolios can decrease your overall portfolio volatility.
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments |